KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities (2016 - 2025)

Historic Total Liabilities for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $11.2 million.

  • TherapeuticsMD's Total Liabilities fell 988.12% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 988.12%. This contributed to the annual value of $11.5 million for FY2024, which is 1832.83% down from last year.
  • Per TherapeuticsMD's latest filing, its Total Liabilities stood at $11.2 million for Q3 2025, which was down 988.12% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Total Liabilities ranged from a high of $274.0 million in Q1 2022 and a low of $11.2 million during Q2 2025
  • For the 5-year period, TherapeuticsMD's Total Liabilities averaged around $99.6 million, with its median value being $22.5 million (2023).
  • In the last 5 years, TherapeuticsMD's Total Liabilities surged by 17599.16% in 2021 and then plummeted by 8993.4% in 2023.
  • TherapeuticsMD's Total Liabilities (Quarter) stood at $263.1 million in 2021, then tumbled by 78.98% to $55.3 million in 2022, then plummeted by 74.65% to $14.0 million in 2023, then fell by 18.33% to $11.5 million in 2024, then dropped by 1.96% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q3 2025, $11.2 million for Q2 2025, and $11.5 million during Q1 2025.